SteelPeak Wealth LLC Purchases New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

SteelPeak Wealth LLC acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the second quarter, Holdings Channel.com reports. The firm acquired 21,532 shares of the company’s stock, valued at approximately $161,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. National Bank of Canada FI boosted its stake in Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares during the last quarter. Wedmont Private Capital boosted its holdings in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after purchasing an additional 2,000 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. Arizona State Retirement System lifted its position in Recursion Pharmaceuticals by 8.5% during the fourth quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock worth $394,000 after buying an additional 3,125 shares in the last quarter. Finally, Green Alpha Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 6.7% in the first quarter. Green Alpha Advisors LLC now owns 72,434 shares of the company’s stock valued at $722,000 after purchasing an additional 4,563 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RXRX. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a report on Friday, August 9th. KeyCorp decreased their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX traded up $0.41 during midday trading on Thursday, hitting $6.69. 4,986,472 shares of the company’s stock were exchanged, compared to its average volume of 6,052,134. The firm’s fifty day simple moving average is $7.97 and its 200-day simple moving average is $9.24. The company has a market cap of $1.59 billion, a PE ratio of -4.18 and a beta of 0.83. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 86.35%. The firm had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same period in the previous year, the firm posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $9.17, for a total transaction of $104,968.99. Following the transaction, the director now directly owns 7,186,913 shares in the company, valued at $65,903,992.21. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $8.78, for a total value of $26,340.00. Following the sale, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $9.17, for a total value of $104,968.99. Following the completion of the sale, the director now directly owns 7,186,913 shares in the company, valued at approximately $65,903,992.21. The disclosure for this sale can be found here. Insiders sold a total of 258,682 shares of company stock valued at $2,040,718 over the last three months. 15.75% of the stock is currently owned by company insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.